Medtronic Announces Retirement of EVP of Operations Gregory L. Smith Amid Strategic IPO Filing for Diabetes Business

Medtronic recently disclosed that Gregory L. Smith, Executive Vice President of Corporate Operations, has formally notified the company of his decision to retire.

Gregory L. Smith

According to an 8-K filing submitted to the U.S. Securities and Exchange Commission on November 3, 2025, this senior executive, who has over 30 years of experience in the supply chain field, will officially retire on December 2. His intention to leave was reported to the company on November 1.

Smith's Career Move After Retirement: Transitioning to Private Equity, Joining an Undisclosed Firm

According to the equity compensation plan disclosed by Medtronic, he will receive accelerated vesting treatment for unexercised equity, specifically including full vesting of unvested stock options, as well as continued vesting eligibility for restricted stock units (RSUs) and performance stock units (PSUs). The company did not provide further details on succession planning or specific retirement arrangements.

Looking back on his career,Smith joined Medtronic in 2021 as Executive Vice President of Global Operations and Supply Chain, having previously served as Executive Vice President of Walmart U.S. Supply Chain.During his tenure at Walmart, he led the implementation of a supply chain reform strategy., with the aim of increasing sales and reducing costs while creating a positive work environment.

In terms of supply chain reform concepts, Smith systematically elaborated on Medtronic's strategic transformation path in an interview in 2022.He proposed to compress the suppliers into a more strategically valuable group of partners, emphasizing the five core standards of "quality, service, cost competitiveness, continuous improvement, and collaborative innovation."Lead the identification of supply chain gaps,淘汰未达标供应商, while cultivating strategic partners capable of co-developing innovative products and improving delivery efficiency.

Industry insiders pointed out that the supply chain reform promoted by Smith at Medtronic has industry示范significance. By strengthening strategic supplier cooperation and optimizing the supply chain structure, Medtronic not only achieved its cost control objectives but also built a more resilient innovative supply chain system in the medical device industry.

After the executive changes, how the company will continue the achievements of this strategic transformation will become a key focus for the capital market.